These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936 [TBL] [Abstract][Full Text] [Related]
33. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Jordan JT; Sun W; Hussain SF; DeAngulo G; Prabhu SS; Heimberger AB Cancer Immunol Immunother; 2008 Jan; 57(1):123-31. PubMed ID: 17522861 [TBL] [Abstract][Full Text] [Related]
34. Glioma-derived T cell immunoglobulin- and mucin domain-containing molecule-4 (TIM4) contributes to tumor tolerance. Xu L; Xiao H; Xu M; Zhou C; Yi L; Liang H J Biol Chem; 2011 Oct; 286(42):36694-9. PubMed ID: 21896488 [TBL] [Abstract][Full Text] [Related]
37. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma. Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997 [TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for glioma: Current management and future application. Xu S; Tang L; Li X; Fan F; Liu Z Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356 [TBL] [Abstract][Full Text] [Related]
39. Adoptive immunotherapy for malignant glioma. Mitchell DA; Fecci PE; Sampson JH Cancer J; 2003; 9(3):157-66. PubMed ID: 12952301 [TBL] [Abstract][Full Text] [Related]
40. Immunologic approaches to therapy for brain tumors. Paul DB; Kruse CA Curr Neurol Neurosci Rep; 2001 May; 1(3):238-44. PubMed ID: 11898524 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]